New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Researchers describe a new method to test cancer drug toxicity

Researchers describe a new method to test cancer drug toxicity

by Tufts UniversityCredit: Pixabay/CC0 Public DomainFor people with cancer, chemotherapy saves lives, but for some patients, the treatment comes with a side effect—heart damage. Screening cancer
Oncology February 18,2024
Researchers describe a new method to test cancer drug toxicity

Researchers describe a new method to test cancer drug toxicity

by Tufts UniversityCredit: Pixabay/CC0 Public DomainFor people with cancer, chemotherapy saves lives, but for some patients, the treatment comes with a side effect—heart damage. Screening cancer
Oncology February 18,2024
Study: Uncertainty over cancer risk and perceived risk heighten with breast density awareness after mammography

Study: Uncertainty over cancer risk and perceived risk heighten with breast density awareness after mammography

by Columbia University's Mailman School of Public HealthCredit: Unsplash/CC0 Public DomainAwareness of breast density appears to increase one's perceived breast cancer risk for a short ti
Oncology February 18,2024
Study: Uncertainty over cancer risk and perceived risk heighten with breast density awareness after mammography

Study: Uncertainty over cancer risk and perceived risk heighten with breast density awareness after mammography

by Columbia University's Mailman School of Public HealthCredit: Unsplash/CC0 Public DomainAwareness of breast density appears to increase one's perceived breast cancer risk for a short ti
Oncology February 18,2024
Research uncovers alternate mechanism for producing key protein in metastatic prostate cancer

Research uncovers alternate mechanism for producing key protein in metastatic prostate cancer

by Dana-Farber Cancer InstituteCredit: Pixabay/CC0 Public DomainLike the better-known prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA) is a biomarker that can tell physi
Oncology February 18,2024
Research uncovers alternate mechanism for producing key protein in metastatic prostate cancer

Research uncovers alternate mechanism for producing key protein in metastatic prostate cancer

by Dana-Farber Cancer InstituteCredit: Pixabay/CC0 Public DomainLike the better-known prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA) is a biomarker that can tell physi
Oncology February 18,2024
Long-term pancreatic cancer survivors report excellent post-surgery quality of life

Long-term pancreatic cancer survivors report excellent post-surgery quality of life

by Chloe Corey,Mayo ClinicCredit: Mayo Clinic News NetworkPancreatic cancer is considered the most lethal cancer in the human body. But new treatment advances are improving outcomes for patients
Oncology February 18,2024
Long-term pancreatic cancer survivors report excellent post-surgery quality of life

Long-term pancreatic cancer survivors report excellent post-surgery quality of life

by Chloe Corey,Mayo ClinicCredit: Mayo Clinic News NetworkPancreatic cancer is considered the most lethal cancer in the human body. But new treatment advances are improving outcomes for patients
Oncology February 18,2024
Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis Bests Standard Regimen in Phase III Study

Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis Bests Standard Regimen in Phase III Study

October 2023Katie RobinsonPatients undergoing a human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplantation (alloHCT) with reduced-intensity conditioning who received a prophyl
Oncology February 18,2024
Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis Bests Standard Regimen in Phase III Study

Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis Bests Standard Regimen in Phase III Study

October 2023Katie RobinsonPatients undergoing a human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplantation (alloHCT) with reduced-intensity conditioning who received a prophyl
Oncology February 18,2024
Study outlines opportunities to achieve Cancer Moonshot goal of reducing cancer death rates

Study outlines opportunities to achieve Cancer Moonshot goal of reducing cancer death rates

by National Institutes of HealthTo achieve the Cancer Moonshot goal, cancer death rates must decline faster. Credit: Shiels M, et al.Cancer Discovery, 2023Researchers from the National Inst
Oncology February 18,2024
Study outlines opportunities to achieve Cancer Moonshot goal of reducing cancer death rates

Study outlines opportunities to achieve Cancer Moonshot goal of reducing cancer death rates

by National Institutes of HealthTo achieve the Cancer Moonshot goal, cancer death rates must decline faster. Credit: Shiels M, et al.Cancer Discovery, 2023Researchers from the National Inst
Oncology February 18,2024
Molecule Linking Cancer Driver and Cell Death Genes May Be Effective Against DLBCL

Molecule Linking Cancer Driver and Cell Death Genes May Be Effective Against DLBCL

November 2023Thomas R. CollinsMolecules that link cancer driver genes and promoters of cell death genes produce potent killing of diffuse large B-cell lymphoma (DLBCL) cells, according to findings pub
Oncology February 18,2024
Molecule Linking Cancer Driver and Cell Death Genes May Be Effective Against DLBCL

Molecule Linking Cancer Driver and Cell Death Genes May Be Effective Against DLBCL

November 2023Thomas R. CollinsMolecules that link cancer driver genes and promoters of cell death genes produce potent killing of diffuse large B-cell lymphoma (DLBCL) cells, according to findings pub
Oncology February 18,2024
IKZF1 Alterations an Independent Marker of AML Risk

IKZF1 Alterations an Independent Marker of AML Risk

February 2024Leah LawrenceMutatedIKZF1was an independent marker of adverse risk in patients with acute myeloid leukemia (AML), and patients whose AML had these alterations were at higher r
Oncology February 18,2024
IKZF1 Alterations an Independent Marker of AML Risk

IKZF1 Alterations an Independent Marker of AML Risk

February 2024Leah LawrenceMutatedIKZF1was an independent marker of adverse risk in patients with acute myeloid leukemia (AML), and patients whose AML had these alterations were at higher r
Oncology February 18,2024
FDA Approves Two Cell-Based SCD Gene Therapies

FDA Approves Two Cell-Based SCD Gene Therapies

February 2024The U.S. Food and Drug Administration (FDA) approved exagamglogene autotemcel (exa-cel) and lovotibeglogene autotemcel (lovo-cel) for the treatment of sickle cell disease (SCD) in patient
Oncology February 18,2024
FDA Approves Two Cell-Based SCD Gene Therapies

FDA Approves Two Cell-Based SCD Gene Therapies

February 2024The U.S. Food and Drug Administration (FDA) approved exagamglogene autotemcel (exa-cel) and lovotibeglogene autotemcel (lovo-cel) for the treatment of sickle cell disease (SCD) in patient
Oncology February 18,2024
Isa-Kd Prolongs PFS to Almost Three Years in Early Relapsed MM Follow-up Study

Isa-Kd Prolongs PFS to Almost Three Years in Early Relapsed MM Follow-up Study

August 2023Katie RobinsonIn patients with early relapsed multiple myeloma (MM), the addition of the anti-CD38 antibody isatuximab (Isa) to carfilzomib-dexamethasone (Kd) maintained the improved progre
Orthopedics & Sports medicine February 18,2024
Isa-Kd Prolongs PFS to Almost Three Years in Early Relapsed MM Follow-up Study

Isa-Kd Prolongs PFS to Almost Three Years in Early Relapsed MM Follow-up Study

August 2023Katie RobinsonIn patients with early relapsed multiple myeloma (MM), the addition of the anti-CD38 antibody isatuximab (Isa) to carfilzomib-dexamethasone (Kd) maintained the improved progre
Orthopedics & Sports medicine February 18,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com